Company
Logomix Inc.
Maximize the potential of cells by our cellular system engineering
Also known as Logomix, Logomix Biotechnology, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- San Carlos, CA, United States
- Founded
- 2025
- Legal name
- Logomix Biotechnology, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Logomix is transforming iPSC engineering with Geno-Writing™, a groundbreaking large-scale cellular system engineering platform. Purpose-built for ex vivo applications, Geno-Writing™ enables rapid, precise, and megabase-scale modifications in human iPSCs to maximize their full therapeutic potential. We are building the foundational technology to bring innovative, scalable cell treatments to patients worldwide.
Funding snapshot
- Total raised
- $19MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Undisclosed, $19M2025-07-30
Funding rounds
- Round, 2025
- $19M2025-07-30, Company stated
Products
- Other
- Geno-Writing™
Loading relationship preview